1
Country: Sweden | Funding: $33.6M
Elypta is developing MIRAM - metabolomics-based liquid biopsy test for the early detection of cancer. MIRAM utilizes state-of-the-art laboratory methods for the extraction and detection of glycosaminoglycans (GAGs), delivering high and reliable performance in a standardized and scalable manner. The method is based on enzymatic digestion, which depolymerizes GAGs into disaccharides. Measurements can be performed in a wide range of research samples, such as blood, urine, tissue, cell cultures, and other biological fluids. Relatively small sample volumes are required to obtain accurate results across the entire glycosaminoglycan profile. The company is conducting a series of clinical studies to evaluate the effectiveness of its liquid biopsy in various cancer types.
Elypta is developing MIRAM - metabolomics-based liquid biopsy test for the early detection of cancer. MIRAM utilizes state-of-the-art laboratory methods for the extraction and detection of glycosaminoglycans (GAGs), delivering high and reliable performance in a standardized and scalable manner. The method is based on enzymatic digestion, which depolymerizes GAGs into disaccharides. Measurements can be performed in a wide range of research samples, such as blood, urine, tissue, cell cultures, and other biological fluids. Relatively small sample volumes are required to obtain accurate results across the entire glycosaminoglycan profile. The company is conducting a series of clinical studies to evaluate the effectiveness of its liquid biopsy in various cancer types.
2
Country: USA | Funding: $2B
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
3
Country: USA | Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
4
Country: USA | Funding: $1.5B
Freenome has developed blood test for colorectal cancer detection based on artificial intelligence. Freenome's technology combines computational biology, machine learning and various data types to detect the most subtle signs of cancer, even in the earliest stages. In addition to colon cancer, the company is developing a test for lung cancer detection. Acquired by Perceptive Capital Solutions
Freenome has developed blood test for colorectal cancer detection based on artificial intelligence. Freenome's technology combines computational biology, machine learning and various data types to detect the most subtle signs of cancer, even in the earliest stages. In addition to colon cancer, the company is developing a test for lung cancer detection. Acquired by Perceptive Capital Solutions
5
Country: USA | Funding: $925.9M
NeoGenomics is a reference laboratory for oncology research providing cancer testing services. It offers healthcare institutions a portfolio of over 500 solutions covering all major research methods, including single-gene molecular testing, immunohistochemistry, flow cytometry, fluorescence in situ hybridization, DNA and RNA next-generation sequencing and full-genome profiling. The company performs tissue analysis, liquid biopsy and blood testing to generate accurate and actionable data for personalized treatment. NeoGenomics also collaborates with pharmaceutical companies to develop new therapies for precision oncology. With one of the largest oncology databases, containing over 2 million unique patient profiles, the company optimizes clinical trial participant recruitment and treatment outcome assessment.
NeoGenomics is a reference laboratory for oncology research providing cancer testing services. It offers healthcare institutions a portfolio of over 500 solutions covering all major research methods, including single-gene molecular testing, immunohistochemistry, flow cytometry, fluorescence in situ hybridization, DNA and RNA next-generation sequencing and full-genome profiling. The company performs tissue analysis, liquid biopsy and blood testing to generate accurate and actionable data for personalized treatment. NeoGenomics also collaborates with pharmaceutical companies to develop new therapies for precision oncology. With one of the largest oncology databases, containing over 2 million unique patient profiles, the company optimizes clinical trial participant recruitment and treatment outcome assessment.
6
Country: Ireland | Funding: $708M
LetsGetChecked offers a health test kit service so that you can take various common laboratory tests from the comfort of your home
LetsGetChecked offers a health test kit service so that you can take various common laboratory tests from the comfort of your home
7
Country: USA | Funding: $369.8M
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
Human Longevity is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
8
Country: USA | Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
9
Country: USA | Funding: $354M
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
10
Country: USA | Funding: $325M
EverlyWell is a digital health platform that provides at-home health tests and lab results.
EverlyWell is a digital health platform that provides at-home health tests and lab results.
11
Country: USA | Funding: $316.6M
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
12
Country: USA | Funding: $244.4M
InterVenn Biosciences is a liquid biopsy company pioneering the development of clinically useful glycoproteomic diagnostics. It has combined the molecular resolution of mass spectrometry with the power of artificial intelligence to create a unique platform for discovering new biomarkers, providing more effective treatments, developing precision medicine clinical trials, and identifying new targets. The company has also developed GlcyoKnow Ovarian, a laboratory test for assessing the risk of malignancy in confirmed pelvic lesions prior to planned surgery. It complements imaging data and clinical assessment, facilitating more informed and personalized treatment decisions.
InterVenn Biosciences is a liquid biopsy company pioneering the development of clinically useful glycoproteomic diagnostics. It has combined the molecular resolution of mass spectrometry with the power of artificial intelligence to create a unique platform for discovering new biomarkers, providing more effective treatments, developing precision medicine clinical trials, and identifying new targets. The company has also developed GlcyoKnow Ovarian, a laboratory test for assessing the risk of malignancy in confirmed pelvic lesions prior to planned surgery. It complements imaging data and clinical assessment, facilitating more informed and personalized treatment decisions.
13
Country: USA | Funding: $154.8M
Genalyte is guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes.
Genalyte is guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes.
14
Country: USA | Funding: $150.1M
Athelas develops an in-home blood diagnostic device designed to monitor the immune system from a drop of blood.
Athelas develops an in-home blood diagnostic device designed to monitor the immune system from a drop of blood.
15
Country: USA | Funding: $135.6M
Tasso is revolutionizing diagnostics by creating technologies for blood sample collection that place the user at the center of process. Our wearable blood collection system, the HemoLinkTM, is being developed to improve the user experience as well as enable both healthcare consumers and providers with convenient access to reliable laboratory test results.
Tasso is revolutionizing diagnostics by creating technologies for blood sample collection that place the user at the center of process. Our wearable blood collection system, the HemoLinkTM, is being developed to improve the user experience as well as enable both healthcare consumers and providers with convenient access to reliable laboratory test results.
16
Country: Israel | Funding: $125.1M
Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology.
Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology.
17
Country: Israel | Funding: $123.8M
Sight Diagnostics aims to bring affordable, scalable and accurate blood diagnostics to the point-of-care, thereby accelerating better patient outcomes and improving healthcare for all. Sight has developed an artificial intelligence-driven platform for blood analysis and infectious disease diagnostics based on its proprietary machine-vision technology.
Sight Diagnostics aims to bring affordable, scalable and accurate blood diagnostics to the point-of-care, thereby accelerating better patient outcomes and improving healthcare for all. Sight has developed an artificial intelligence-driven platform for blood analysis and infectious disease diagnostics based on its proprietary machine-vision technology.
18
Country: USA | Funding: $112.3M
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
19
Country: USA | Funding: $108M
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
20
Country: USA | Funding: $98.2M
We are a privately held medical technology company focused on developing innovative blood collection devices used in research and clinical testing. Our mission is to eliminate the barriers to successful blood sample collection and testing for health care professionals and consumers with simple, safe, mobile, and nearly painless technologies.
We are a privately held medical technology company focused on developing innovative blood collection devices used in research and clinical testing. Our mission is to eliminate the barriers to successful blood sample collection and testing for health care professionals and consumers with simple, safe, mobile, and nearly painless technologies.
21
Country: USA | Funding: $91M
Q Bio operates as a platform that provides a physical health picture of the users.
Q Bio operates as a platform that provides a physical health picture of the users.
22
Country: Israel | Funding: $83M
Nucleix is developing liquid biopsy technology for the early detection of cancer. Its first product - Bladder EpiCheck test is certified for the diagnosis of primary and recurrent bladder and upper urinary tract cancer. This in vitro diagnostic device detects DNA methylation patterns in urine associated with urothelial carcinoma. It is intended for use as non-invasive method for monitoring tumor recurrence in conjunction with standard diagnostic procedures. The test analyzes small, disease-specific changes in DNA methylation markers, enabling the detection of cancer. The test has demonstrated high sensitivity (91%) for high-grade tumors, which are important to detect because they are aggressive and, if not treated immediately, can progress to invasive cancer. The company is also developing Lung EpiCheck to detect lung cancer at an early stage in high-risk individuals using a simple blood test.
Nucleix is developing liquid biopsy technology for the early detection of cancer. Its first product - Bladder EpiCheck test is certified for the diagnosis of primary and recurrent bladder and upper urinary tract cancer. This in vitro diagnostic device detects DNA methylation patterns in urine associated with urothelial carcinoma. It is intended for use as non-invasive method for monitoring tumor recurrence in conjunction with standard diagnostic procedures. The test analyzes small, disease-specific changes in DNA methylation markers, enabling the detection of cancer. The test has demonstrated high sensitivity (91%) for high-grade tumors, which are important to detect because they are aggressive and, if not treated immediately, can progress to invasive cancer. The company is also developing Lung EpiCheck to detect lung cancer at an early stage in high-risk individuals using a simple blood test.
23
Country: USA | Funding: $74M
Truvian is a transformational diagnostic company bringing lab-accurate results to the point-of-action where consumers engage healthcare providers to lead healthier lives.
Truvian is a transformational diagnostic company bringing lab-accurate results to the point-of-action where consumers engage healthcare providers to lead healthier lives.
24
Country: Canada | Funding: $48M
Vital is reimagining lab testing to enable radically accessible care.
Vital is reimagining lab testing to enable radically accessible care.
25
Country: India | Funding: $47.1M
Our view on healthcare is that, like much else, it should reach our homes – conveniently and affordably. We believe being connected to your doctor matters. A personal connect and context in healthcare cannot be replaced. Effective medicine will be when online and offline worlds combine. Our efforts will be to create services and products that doctors can use with their patients in clinic or remotely at their homes to better assess and diagnose patients health and provide the right treatment.
Our view on healthcare is that, like much else, it should reach our homes – conveniently and affordably. We believe being connected to your doctor matters. A personal connect and context in healthcare cannot be replaced. Effective medicine will be when online and offline worlds combine. Our efforts will be to create services and products that doctors can use with their patients in clinic or remotely at their homes to better assess and diagnose patients health and provide the right treatment.
26
Country: USA | Funding: $40M
Getlabs makes it easy to book lab appointments at your home or office.
Getlabs makes it easy to book lab appointments at your home or office.
27
Country: USA | Funding: $35.4M
Techcyte creates AI-powered digital diagnostic tests to assist labs and clinics with a more efficient diagnostic process.
Techcyte creates AI-powered digital diagnostic tests to assist labs and clinics with a more efficient diagnostic process.
28
Country: Netherlands | Funding: €32M
Vitestro transform patient care with autonomous blood drawing technology. The company's device utilizes ultrasound-guided, AI-based 3D reconstruction with robotic needle insertion to collect a user's blood.
Vitestro transform patient care with autonomous blood drawing technology. The company's device utilizes ultrasound-guided, AI-based 3D reconstruction with robotic needle insertion to collect a user's blood.
29
Country: Singapore | Funding: $29.2M
Lucence is a genomic medicine company guiding cancer care across diverse patient journeys with world-leading profiling technology. We invent a full spectrum of cancer diagnostics covering early-stage screening to late-stage treatment selection with a special focus on common cancers
Lucence is a genomic medicine company guiding cancer care across diverse patient journeys with world-leading profiling technology. We invent a full spectrum of cancer diagnostics covering early-stage screening to late-stage treatment selection with a special focus on common cancers
30
Country: Taiwan | Funding: $22M
iXensor created the world first FDA approved smartphone camera-based blood test system for health care.
iXensor created the world first FDA approved smartphone camera-based blood test system for health care.
31
Country: Switzerland | Funding: $21.3M
ProteoMediX is specialized in the identification of novel biomarkers for the early detection of cancer. The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.
ProteoMediX is specialized in the identification of novel biomarkers for the early detection of cancer. The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.
32
Country: USA | Funding: $19.1M
MARAbio is a biotech firm that works to detect and prevent severe forms of Autism.
MARAbio is a biotech firm that works to detect and prevent severe forms of Autism.
33
Country: USA | Funding: $18.2M
InsideTracker is a personal nutrition model by Segterra. Sophisticated, science-based blood analytics, tailored just for you. Get your personalized nutrition and lifestyle recommendations now. A simple blood test and survey will enable us to derive your unique optimal zones and tailor your recommendations to your background, lifestyle and food preferences.
InsideTracker is a personal nutrition model by Segterra. Sophisticated, science-based blood analytics, tailored just for you. Get your personalized nutrition and lifestyle recommendations now. A simple blood test and survey will enable us to derive your unique optimal zones and tailor your recommendations to your background, lifestyle and food preferences.
34
Country: UK | Funding: $14.7M
Thriva offers a personalized at-home finger-prick blood test which enables individuals to easily track and improve health.
Thriva offers a personalized at-home finger-prick blood test which enables individuals to easily track and improve health.
35
Country: USA | Funding: $15M
Fibronostics is a non-invasive algorithm-based diagnostics company.
Fibronostics is a non-invasive algorithm-based diagnostics company.
36
Country: Switzerland | Funding: $8.1M
1Drop Diagnostics is a cutting edge medical diagnostics and life science company. They combine the best techniques from microfluidics, biochemistry, photonics and information technology to build high performance point-of-care diagnostics devices.
1Drop Diagnostics is a cutting edge medical diagnostics and life science company. They combine the best techniques from microfluidics, biochemistry, photonics and information technology to build high performance point-of-care diagnostics devices.
37
Country: UK | Funding: £5.5M
Level Zero Health focuses on advanced biosensor technology to collect new types of data by combining biochemistry and nanotechnology.
Level Zero Health focuses on advanced biosensor technology to collect new types of data by combining biochemistry and nanotechnology.
39
Country: Canada | Funding: CA$6.8M
Nanostics is focused on development and commercialization of novel, non-invasive diagnostic tests for cancer.
Nanostics is focused on development and commercialization of novel, non-invasive diagnostic tests for cancer.
40
Country: UK | Funding: $3.1M
Kalium Health develops personalised electrolyte monitoring test
Kalium Health develops personalised electrolyte monitoring test
41
Country: USA | Funding: $2.4M
Delee is a medical device company that aims to revolutionize how cancer is diagnosed and managed. That is why we developed CytoCatch, a patent pending technology that enables the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness.
Delee is a medical device company that aims to revolutionize how cancer is diagnosed and managed. That is why we developed CytoCatch, a patent pending technology that enables the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness.
42
Country: USA | Funding: $619.9K
Tymora Analytical Operations discovered a way to detect and monitor breast cancer using a simple blood test and bladder cancer using a urine test.
Tymora Analytical Operations discovered a way to detect and monitor breast cancer using a simple blood test and bladder cancer using a urine test.
43
Country: Chile | Funding: $1.1M
Ilico Genetics is a subsidiary of the Pontificia Universidad Católica de Chile, that developed GastroMDx - liquid biopsy test for the early detection of gastric cancer. According to the company, it is the first methylated DNA-based molecular test specifically designed for the early detection of gastric cancer - detecting the disease years before the current "gold standard" esophagogastroduodenoscopy (EGD) can detect it. GastroMDx uses molecular biomarkers based on genetic and epigenetic signatures - subtle changes in DNA or RNA expression patterns - that can indicate the early presence of malignancy.
Ilico Genetics is a subsidiary of the Pontificia Universidad Católica de Chile, that developed GastroMDx - liquid biopsy test for the early detection of gastric cancer. According to the company, it is the first methylated DNA-based molecular test specifically designed for the early detection of gastric cancer - detecting the disease years before the current "gold standard" esophagogastroduodenoscopy (EGD) can detect it. GastroMDx uses molecular biomarkers based on genetic and epigenetic signatures - subtle changes in DNA or RNA expression patterns - that can indicate the early presence of malignancy.
44
Country: USA | Funding: $750K
Spot On Sciences develops and markets innovative devices that revolutionize collection and storage of biological fluids for medical research and testing. Based in Austin, TX, initial products, HemaForm and HemaSpot, enable remote collection of blood samples offering solutions for multiple markets including clinical trials, biobanking, home-based wellness testing, military field medicine and population studies.
Spot On Sciences develops and markets innovative devices that revolutionize collection and storage of biological fluids for medical research and testing. Based in Austin, TX, initial products, HemaForm and HemaSpot, enable remote collection of blood samples offering solutions for multiple markets including clinical trials, biobanking, home-based wellness testing, military field medicine and population studies.
45
Country: USA
GattaCo is an medical diagnostics company that has developed a revolutionary new A-PON device that was successfully tested on SpaceX’s Inspiration4 mission.
GattaCo is an medical diagnostics company that has developed a revolutionary new A-PON device that was successfully tested on SpaceX’s Inspiration4 mission.
46
Country: USA
Haemanthus seeks to deliver “human health optimization” through blood testing. The company has developed a machine that uses lasers to analyze blood, saliva, and urine samples to detect cancer and infections.
Haemanthus seeks to deliver “human health optimization” through blood testing. The company has developed a machine that uses lasers to analyze blood, saliva, and urine samples to detect cancer and infections.
